Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:52:40.655Z.
Calculation as of: 2026-10-06T14:52:40.655Z.
Quote observation: 2026-10-06T14:50:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 97f82c903e8e6ec217280dce7f3fe4a68629f44b5a27270464b7740b55d93be6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$350.32M
EV/FCF Ratio
N/A
TTM Avg
50.02x
3Y Avg
37.43x
5Y Avg
35.40x
Market Cap
$354.67M
EV/FCF Ratio
N/A
TTM Avg
6.23x
3Y Avg
6.23x
5Y Avg
6.23x
Market Cap
$357.49M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$335.22M
EV/FCF Ratio
N/A
TTM Avg
114948.95x
3Y Avg
114948.95x
5Y Avg
114948.95x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $350.35M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $350.32M | N/A | 50.02x | 37.43x | 35.40x |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.67M | N/A | 6.23x | 6.23x | 6.23x |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $345.41M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $357.49M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.89M | 9.97x | 9.65x | 69.46x | 48.92x |
| Ocugen, Inc. (OCGN)vs › | $356.64M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $335.22M | N/A | 114948.95x | 114948.95x | 114948.95x |
| ClearPoint Neuro, Inc. (CLPT)vs › | $331.54M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $371.16M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
